AAP
ALXN

Ardsley Advisory Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Ardsley Advisory Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-30,000
Closed -$3.59M – 183
2017
Q4 		$3.59M Buy
+30,000
New +$3.65M 0.44% 50

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Ardsley Advisory Partners's ALXN Position: Q4 2020 in Review

Ardsley Advisory Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 2,500 shares — an estimated $286K sold.

Ardsley Advisory Partners first reported a position in ALXN in Q1 2017 and held it in 11 quarters. The position peaked at $24.1M in Q3 2017. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Ardsley Advisory Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 2,500 Alexion Pharmaceuticals shares in Q4 2020, an estimated $286K.
  • Ardsley Advisory Partners first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 11 quarters.
  • Ardsley Advisory Partners's Alexion Pharmaceuticals position peaked at $24.1M in Q3 2017.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Ardsley Advisory Partners's 13F filing for Q4 2020, filed 16 Feb 2021.